Table 2.
Univariate analysis of factors at baseline potentially associated with sustained virological response
| SVR | No SVR | p-value | |
|---|---|---|---|
| Age (years)a | 44 | 43 | 0.595c |
| Gender | 0.315d | ||
| Female | 50 (40) | 17 (31) | |
| Male | 75 (60) | 38 (69) | |
| log10 viral load (IU/L)a | 5.68 | 5.75 | 0.861c |
| Genotype | 0.248d | ||
| 2 | 54 (43) | 18 (33) | |
| 3 | 71 (57) | 37 (67) | |
| METAVIR fibrosis score | 0.004d | ||
| 0 | 18 (14) | 1 (2) | |
| 1 | 33 (26) | 11 (20) | |
| 2 | 46 (37) | 18 (33) | |
| 3 | 19 (15) | 13 (24) | |
| 4 | 9 (7) | 12 (22) | |
| BMI (kg/m2)a, b | 27 | 28 | 0.018c |
| Assigned treatment duratione | 0.033d | ||
| 24 weeks | 94 (75) | 32 (58) | |
| 48 weeks | 31 (25) | 23 (42) |
Values given in parentheses are percentages.
a
Mean.
b
One patient did not have data available for BMI.
c
Wilcoxon rank-sum test.
d
Fisher’s exact test.
e
When the 12 patients (five from 24-week therapy and seven from 48-week therapy) who withdrew early (before week 12) due to poor tolerance or adverse events are excluded, this factor loses its significance (P = 0.167).